ACRG#1 |
non-mesenchymal |
MSI |
-0.17 |
negative |
MSS |
partial loss |
intestinal |
moderately differentiated adenocarcinoma |
IB |
ACRG#2 |
mesenchymal |
MSS/EMT |
0.32 |
negative |
MSS |
preserved |
diffuse |
signet ring cell carcinoma |
III |
ACRG#3 |
mesenchymal |
MSS/EMT |
0.37 |
positive |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#4 |
mesenchymal |
MSS/EMT |
0.53 |
negative |
MSS |
preserved |
mixed |
mucinous adenocarcinoma |
II |
ACRG#5 |
mesenchymal |
MSS/EMT |
0.19 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#6 |
non-mesenchymal |
MSI |
0.24 |
negative |
MSS |
loss |
diffuse |
signet ring cell carcinoma |
III |
ACRG#7 |
mesenchymal |
MSS/EMT |
0.3 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#8 |
mesenchymal |
MSS/EMT |
0.12 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#9 |
mesenchymal |
MSS/EMT |
0.2 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
III |
ACRG#10 |
non-mesenchymal |
MSS/p53 active |
0.03 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
IB |
ACRG#11 |
non-mesenchymal |
MSI |
-0.7 |
negative |
MSI-high |
loss |
diffuse |
moderately differentiated adenocarcinoma |
IB |
ACRG#12 |
non-mesenchymal |
MSS/p53 active |
-0.3 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
IB |
ACRG#13 |
non-mesenchymal |
MSS/p53 inactive |
-0.44 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#14 |
non-mesenchymal |
MSI |
-0.27 |
negative |
MSI-high |
loss |
diffuse |
moderately differentiated adenocarcinoma |
II |
ACRG#15 |
non-mesenchymal |
MSS/p53 active |
-0.28 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#16 |
non-mesenchymal |
MSS/p53 active |
-0.15 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#17 |
non-mesenchymal |
MSS/p53 inactive |
-0.15 |
ND |
ND |
preserved |
intestinal |
poorly differentiated adenocarcinoma |
IV |
ACRG#18 |
non-mesenchymal |
MSI |
-0.52 |
negative |
MSS |
loss |
intestinal |
moderately differentiated adenocarcinoma |
IB |
ACRG#19 |
non-mesenchymal |
MSS/p53 inactive |
-0.08 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
III |
ACRG#20 |
non-mesenchymal |
MSS/p53 inactive |
-0.49 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
III |
ACRG#21 |
non-mesenchymal |
MSI |
-0.72 |
negative |
MSS |
loss |
mixed |
moderately differentiated adenocarcinoma |
III |
ACRG#22 |
non-mesenchymal |
MSS/p53 active |
0.01 |
negative |
MSS |
preserved |
intestinal |
well differentiated adenocarcinoma |
II |
ACRG#23 |
non-mesenchymal |
MSS/p53 inactive |
-0.24 |
positive |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#24 |
non-mesenchymal |
MSS/p53 inactive |
0.01 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#25 |
non-mesenchymal |
MSI |
0.02 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#26 |
mesenchymal |
MSS/EMT |
0.26 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#27 |
non-mesenchymal |
MSS/p53 inactive |
-0.58 |
negative |
MSI-high |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
II |
ACRG#28 |
non-mesenchymal |
MSS/p53 active |
0.06 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#29 |
non-mesenchymal |
MSS/p53 inactive |
-0.57 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
III |
ACRG#30 |
non-mesenchymal |
MSI |
0.49 |
negative |
MSS |
preserved |
mixed |
moderately differentiated adenocarcinoma |
III |
ACRG#31 |
non-mesenchymal |
MSI |
-0.58 |
ND |
MSI-high |
preserved |
intestinal |
poorly differentiated adenocarcinoma |
IB |
ACRG#32 |
non-mesenchymal |
MSI |
-0.55 |
negative |
MSS |
preserved |
intestinal |
well differentiated adenocarcinoma |
IB |
ACRG#33 |
non-mesenchymal |
MSS/p53 active |
-0.09 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
III |
ACRG#34 |
non-mesenchymal |
MSS/p53 active |
-0.2 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#35 |
non-mesenchymal |
MSS/p53 active |
-0.07 |
negative |
MSS |
preserved |
intestinal |
poorly differentiated adenocarcinoma |
IV |
ACRG#36 |
non-mesenchymal |
MSS/p53 inactive |
-0.01 |
negative |
MSS |
preserved |
diffuse |
signet ring cell carcinoma |
IV |
ACRG#37 |
non-mesenchymal |
MSS/p53 active |
-0.92 |
negative |
MSI-high |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
IV |
ACRG#38 |
non-mesenchymal |
MSI |
-0.29 |
negative |
MSS |
loss |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#39 |
mesenchymal |
MSS/EMT |
-0.01 |
negative |
MSS |
preserved |
diffuse |
signet ring cell carcinoma |
III |
ACRG#40 |
non-mesenchymal |
MSI |
-0.6 |
negative |
MSI-high |
loss |
intestinal |
moderately differentiated adenocarcinoma |
IB |
ACRG#41 |
non-mesenchymal |
MSS/p53 active |
-0.46 |
negative |
MSS |
preserved |
intestinal |
poorly differentiated adenocarcinoma |
III |
ACRG#42 |
non-mesenchymal |
MSS/EMT |
0.12 |
negative |
|
loss |
diffuse |
signet ring cell carcinoma |
IV |
ACRG#43 |
non-mesenchymal |
MSS/p53 active |
-0.22 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
IV |
ACRG#44 |
non-mesenchymal |
MSI |
-0.28 |
negative |
MSS |
loss |
intestinal |
moderately differentiated adenocarcinoma |
IV |
ACRG#45 |
non-mesenchymal |
MSS/p53 active |
0.12 |
positive |
MSS |
preserved |
intestinal |
poorly differentiated adenocarcinoma |
IV |
ACRG#46 |
mesenchymal |
MSS/EMT |
0.32 |
negative |
MSS |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#47 |
non-mesenchymal |
MSS/p53 inactive |
-0.58 |
negative |
MSS |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
II |
ACRG#48 |
mesenchymal |
MSS/EMT |
0.34 |
negative |
MSS |
preserved |
diffuse |
signet ring cell carcinoma |
III |
ACRG#49 |
non-mesenchymal |
MSS/EMT |
-0.44 |
negative |
|
preserved |
diffuse |
signet ring cell carcinoma |
IV |
ACRG#50 |
non-mesenchymal |
MSS/p53 active |
-0.22 |
positive |
|
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#51 |
non-mesenchymal |
MSI |
-0.22 |
negative |
NR24 only MSI |
preserved |
diffuse |
poorly differentiated adenocarcinoma |
IV |
ACRG#52 |
non-mesenchymal |
MSI |
-0.43 |
negative |
NR24 only MSI |
preserved |
intestinal |
moderately differentiated adenocarcinoma |
III |
ACRG#53 |
non-mesenchymal |
MSS/p53 active |
0.22 |
negative |
|
preserved |
diffuse |
mucinous adenocarcinoma |
III |
ACRG#55 |
non-mesenchymal |
MSS/p53 active |
-0.34 |
negative |
|
preserved |
diffuse |
others |
II |
ACRG#56 |
non-mesenchymal |
MSI |
-0.15 |
negative |
|
preserved |
diffuse |
mucinous adenocarcinoma |
III |
ACRG#57 |
non-mesenchymal |
MSS/p53 active |
0.09 |
positive |
|
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#58 |
non-mesenchymal |
MSI |
-0.67 |
negative |
|
loss |
intestinal |
moderately differentiated adenocarcinoma |
IV |
ACRG#59 |
non-mesenchymal |
MSI |
-0.83 |
negative |
|
loss |
intestinal |
poorly differentiated adenocarcinoma |
III |
ACRG#60 |
non-mesenchymal |
MSS/p53 active |
0.27 |
negative |
|
preserved |
intestinal |
poorly differentiated adenocarcinoma |
III |
ACRG#61 |
non-mesenchymal |
MSI |
-0.27 |
294 |
MSI-high |
loss |
00283129 |
67 |
|
ACRG#62 |
non-mesenchymal |
MSS/p53 active |
0.22 |
ND |
|
preserved |
diffuse |
signet ring cell carcinoma |
III |
ACRG#63 |
non-mesenchymal |
MSS/p53 active |
0.01 |
negative |
|
preserved |
intestinal |
poorly differentiated adenocarcinoma |
III |
ACRG#64 |
non-mesenchymal |
MSS/p53 active |
0.08 |
negative |
|
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |
ACRG#65 |
mesenchymal |
MSS/EMT |
-0.07 |
negative |
|
preserved |
intestinal |
poorly differentiated adenocarcinoma |
III |
ACRG#66 |
mesenchymal |
MSS/EMT |
0.45 |
negative |
|
preserved |
diffuse |
signet ring cell carcinoma |
IV |
ACRG#67 |
non-mesenchymal |
MSS/p53 inactive |
-0.2 |
negative |
|
preserved |
intestinal |
moderately differentiated adenocarcinoma |
III |
ACRG#68 |
mesenchymal |
MSS/EMT |
0.29 |
negative |
|
loss |
diffuse |
signet ring cell carcinoma |
IV |
ACRG#69 |
non-mesenchymal |
MSI |
-0.7 |
negative |
|
loss |
mixed |
poorly differentiated adenocarcinoma |
III |
ACRG#70 |
non-mesenchymal |
MSS/p53 active |
-0.44 |
negative |
|
preserved |
intestinal |
papillary adenocarcinoma |
II |
ACRG#71 |
non-mesenchymal |
MSS/p53 active |
0.24 |
positive |
|
preserved |
diffuse |
poorly differentiated adenocarcinoma |
III |